Table 1. Correlation between PD-L1 expression and NSCLC patients clinicopathologic characteristic.

Variable	n (%)	PD-L1 TPS, n (%)			Univariate analysis		Multivariate analysis
		<1%	1%~49%	≥50%	p value	ρ value	p value
Sex (n = 1008)					0.000	−0.139**	0.497
Male	686(68.1)	345	217	124
Female	322(31.9)	202	96	24
Age, y (n = 1008)					0.644	0.015	0.873
≤65	713(70.7)	388	227	98
M65	295(29.3)	159	86	50
Histological type (n = 1008)					0.000	−0.168**	0.044
LUSCs	337(33.4)	148	114	75
LUADs	671(66.6)	399	199	73
Smoking history (n = 435)					0.031	0.103*	0.868
No	218(50.1)	136	64	18
Yes	217(49.9)	120	56	41
Tumor maximum diameter (n = 411)					0.000	0.213**	0.708
≤3	224(54.5)	157	53	14
M3	187(45.5)	97	52	38
Level of differentiation (n = 893)					0.000	0.191**	0.003
Well~ medium	282(31.6)	119	98	65
Poor	611(68.4)	370	176	65
Tumor(T) (n = 408)					0.000	0.240**	0.172
T1	208(51.0)	114	52	12
T2	94(23.0)	59	21	14
T3	61(15.0)	38	13	10
T4	45(11.0)	11	19	15
Region lymph node (N) (n = 408)					0.000	0.329**	0.089
N0	269(65.9)	192	63	14
N1	29(7.1)	14	9	6
N2	63(15.4)	32	17	14
N3	47(11.5)	14	16	17
Metastasis(M) (n = 408)					0.000	0.255**	0.351
M0	363(89.0)	240	84	39
M1	45(11.0)	12	21	12
Clinical stage (n = 408)					0.000	0.328**	0.148
I~II	282(69.1)	201	65	16
III~IV	126(30.9)	51	40	35

Note: ρ refers to Spearman coefficient. ρ value greater than zero means a positive correlation and less than zero means a negative correlation.